# Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

> **NCT01080391** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 792 (actual)

## Conditions studied

- Relapsed Multiple Myeloma

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide
- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT01080391
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-14
- **Primary completion:** 2014-06-16
- **Final completion:** 2017-12-05
- **Target enrollment:** 792 (ACTUAL)
- **Last updated:** 2022-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01080391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01080391, "Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01080391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*